Semax: A Research Overview

Semax is one of the few research peptides with extensive human clinical trial data. Registered as a pharmaceutical in Russia and Ukraine, this ACTH-derived heptapeptide has decades of documented safety and efficacy in neurological research. This guide provides a comprehensive scientific overview.

What is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4–7) fragment, developed collaboratively by the Institute of Molecular Genetics (IMG) at the Russian Academy of Sciences and Moscow State University (MSU). First synthesised in the 1980s, Semax was registered as an approved pharmaceutical in Russia in 1996 for the treatment of ischaemic stroke, transient ischaemic attacks (TIA), optic neuropathy, and cognitive impairment.

Its status as a registered pharmaceutical with published clinical trial data distinguishes it from most research peptides — a key advantage for researchers seeking compounds with established safety and efficacy parameters. The peptide has been used clinically in over 6 million patients in Russia and Eastern Europe.

Known Mechanism of Action

BDNF and NGF Upregulation

Semax's primary and best-characterised mechanism is the potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Research demonstrates that Semax administration significantly increases BDNF mRNA expression in the hippocampus, cerebral cortex, and striatum within hours of administration. This BDNF/NGF upregulation is the central pathway underlying both its acute neuroprotective and chronic nootropic effects.

Dopaminergic and Serotonergic Modulation

Published studies show that Semax modulates central dopaminergic and serotonergic neurotransmission. It increases dopamine and serotonin turnover in the prefrontal cortex and striatum — regions critical for attention, executive function, and mood regulation. These effects are dose-dependent and correlate with behavioural improvements in animal models of cognitive function.

HIF-1α and Ischaemia Protection

In cerebral ischaemia models, Semax upregulates hypoxia-inducible factor 1-alpha (HIF-1α), the master transcriptional regulator of cellular oxygen homeostasis. This activates a cascade of protective genes including erythropoietin (EPO), vascular endothelial growth factor (VEGF), and glucose transporters — collectively reducing infarct volume and improving neurological outcomes.

Anti-Neuroinflammatory Activity

Semax demonstrates anti-neuroinflammatory effects through inhibition of NF-κB and MAPK signalling pathways. This reduces expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in microglial cells — a mechanism relevant to neurodegenerative disease research models.

Clinical Trial Data

Semax has been evaluated in multiple randomised controlled trials:

• Ischaemic Stroke (Phase 3): A multicentre RCT of 268 patients with acute ischaemic stroke demonstrated that 12–18 µg/kg/day intranasal Semax for 10 days significantly improved neurological recovery (NIHSS scores) and functional outcomes (Barthel Index) at 30 days compared to placebo.
• TIA and Cerebrovascular Insufficiency: Studies of 150+ patients showed improved cerebral blood flow velocity (transcranial Doppler), reduced frequency of TIA episodes, and improved cognitive measures at 14 and 30 days.
• Optic Neuropathy: Clinical studies demonstrated improved visual acuity, visual field parameters, and retinal nerve fibre layer thickness in patients receiving intranasal Semax for 14 days.

The cumulative clinical safety database encompasses over 6 million patients with no serious adverse events attributable to Semax in the published literature.

Research Protocols & Dosing

Standard research protocols vary by experimental model. Rodent studies typically use 50–200 µg/kg intranasally or intraperitoneally. Clinical stroke protocols use 12–18 µg/kg/day intranasally (divided doses). Nootropic and cognitive research commonly uses 300–600 µg intranasally given 1–2 times daily, with some protocols using up to 1200 µg/day in divided doses.

Intranasal administration is the standard route for CNS research — the peptide reaches the brain within minutes via olfactory epithelium transport, bypassing the blood-brain barrier. Intranasal Semax demonstrates approximately 10–15% brain bioavailability compared to negligible amounts following intravenous administration.

Stability & Handling

Semax is stable as a lyophilized powder at 2–8°C (refrigerated) for 12+ months. Once reconstituted with bacteriostatic water, it remains stable for 7–14 days at 2–8°C. Semax is soluble in water and saline solutions. Avoid freeze-thaw cycles.

---